tbuckley/cabot-search huggingface dataset:
LOWER ON-TREATMENT LOW-DENSITY LIPOPROTEIN CHOLESTEROL IS ASSOCIATED WITH LOWER CARDIOVASCULAR RISK IN WOMEN: ANALYSES FROM THE ODYSSEY TRIALS OF ALIROCUMAB VERSUS CONTROL
Authors: Antonio Vallejo-Vaz, Henry Ginsberg, Michael Davidson, Robert H. Eckel, Christopher Cannon, Veronica Lee, Laurence Bessac, Robert Pordy, Alexia Letierce, Kausik Ray
Journal: Journal of the American College of Cardiology (2017)
NT-PROBNP, LEFT VENTRICULAR STRUCTURE AND FUNCTION, AND LONG-TERM CARDIOVASCULAR EVENTS: INSIGHTS FROM A PROSPECTIVE POPULATION-BASED COHORT STUDY
Authors: Manan Pareek, Deepak L. Bhatt, Muthiah Vaduganathan, Tor Biering-Sørensen, Jacob E. Møller, Margrét Leósdóttir, Martin Magnusson, Peter M. Nilsson, Michael Olsen
Journal: Journal of the American College of Cardiology (2017)
Survival patterns by line of treatment of stage IV colorectal (CRC) patients from local U.S. oncology practice.
Authors: Charles Kreilick, Susan H Foltz Boklage, Sean D Sullivan, Scott David Ramsey, Sally Haislip, James W. Gilmore, Stephen Szabo, Syam Sarma, Carl V Asche, Satish Valluri, Brian S. Seal
Journal: Journal of Clinical Oncology (2012)

e14141 Background: Stage IV CRC patients have varying survival results from multiple lines of treatment. The objective of this study was to evaluate in a real world context, the impact of adding a third line of chemotherapy to a stage IV CRC population. Methods: The Georgia Cancer Specialist database (2005-2011) was used. Patients with stage IV colon or rectal cancer and treated with chemotherapy were followed from initial CRC diagnosis until death, study end or lost to follow-up. Patients were stratified into lines and type of protocol for treatments. Kaplan-Meier curves were used to compare the overall survival results between lines of therapy. Results: There were 335 patients with confirmed stage IV CRC of which 35% received one protocol, 27% two protocols, and 38% received three or more protocols. The most common first line agents consisted of FOLFOX with or without bevacizumab or FOLFIRI with or without bevacizumab. Some single agent 5FU or 5FU with bevacizumab was observed in first line. The most common second agents were the FOLFOX or FOLFIRI not given in first line. However single agent capecitabine, cetuximab and bevacizumab were observed. In third line similar single agents but more panitumumab and capecitabine combinations were observed. Of those treated with second line (45) and three or more lines (75). The median survival was no different between the patients that received second line and those that went on to a third line (Log-Rank p=0.1249). Conclusions: The addition of adding a third line to a stage IV population that already received a second line failed show an association to increase survival. The benefit of adding a third line may benefit some patients and the particular combination of therapy needs to be explored in future studies.
Erratum: Corrigendum: Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic states
Authors: Ronald D Cohn, Christel van Erp, Jennifer P Habashi, Arshia A Soleimani, Erin C Klein, Matthew T Lisi, Matthew Gamradt, Colette M ap Rhys, Tammy M Holm, Bart L Loeys, Francesco Ramirez, Daniel P Judge, Christopher W Ward, Harry C Dietz
Journal: Nature Medicine (2007)
DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS) SYNDROME ASSOCIATED EOSINOPHILIC MYOCARDITIS TREATED WITH TOFACITINIB AN ORAL JANUS (JAK) KINASE INHIBITOR
Authors: Bani Azari, Mohsin Chowdhury, Ralph Riello, Nitya Sthalekar, Brett King, Tariq Ahmad
Journal: Journal of the American College of Cardiology (2017)
DUAL-ENERGY CORONARY COMPUTED TOMOGRAPHY EVALUATION OF HIGH-RISK ATHEROSCLEROTIC PLAQUE IN SUDDEN CARDIAC DEATH PATIENTS: VALIDATION WITH HISTOPATHOLOGIC GOLD STANDARD
Authors: Asim Rizvi, Fay Lin, Briain O. Hartaigh, Ji Hyun Lee, Donghee Han, Yao Lu, Mahn Won Park, Hadi Mirhedayati Roudsari, Subhi Al'Aref, Ashley Beecy, Khalil Anchouche, Kazuyuki Yahagi, Sho Torii, David Fowler, Robert Kutys, James Earls, Jessica M. Peña, James K. Min, Renu Virmani
Journal: Journal of the American College of Cardiology (2017)
REAL-TIME ULTRASOUND VERSUS FLUOROSCOPY GUIDED ACCESS FOR TRANSCATHETER AORTIC VALVE REPLACEMENT WITH THE SAPIEN 3 VALVE
Authors: Sukhdeep S. Basra, Deborah Tabachnick, John Squiers, Giovanni Filardo, Benjamin Pollock, Molly Szerlip, David Brown, William Brinkman, Katherine Harrington, Paul Grayburn, Michael Mack, J. Michael DiMaio, Srinivasa Potluri
Journal: Journal of the American College of Cardiology (2017)
The Relative Dependency of Chronic Lymphocytic Leukemia (CLL) Cells on Nurselike Cells for in Vitro Survival Is Associated with Overall Survival in Previously Untreated CLL Patients
Authors: Danelle James, Sonia Jain, Maryann Betty, Harrison Malone, Andrew Greaves, Laura Rassenti, Thomas J. Kipps
Journal: Blood (2008)
The effect of obesity on prognosis in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathologic subtypes.
Authors: Marina Pollán, Bella Pajares, Miguel Martin, John Robert Mackey, Ana Lluch, Joaquin Gavila, Charles L. Vogel, Manuel Ruiz Borrego, Lourdes Calvo, Tadeusz Pienkowski, Alvaro Rodriguez-Lescure, Miquel Angel Seguí, Olivier Tredan, Antonio Anton, Manuel Ramos Vazquez, M Carmen Camara, Cesar Rodriguez-Martin, Eva Maria Carrasco, Emilio Alba
Journal: Journal of Clinical Oncology (2013)

1031 Background: According to observational studies, obesity is an unfavourable prognostic factor in breast cancer (BC), regardless of menopausal status and treatment received. Information collected in clinical trials should confirm this effect and serves to test its homogeneity by pathologic subtype. Methods: We retrospectively analysed 5,683 operable BC patients enrolled in four randomized clinical trials (GEICAM/9906, 9805, 2003–02, and BCIRG 001) evaluating adjuvant anthracyclines and taxanes. Our primary aim was to assess the prognostic effect of body mass index (BMI) on disease recurrence, breast cancer mortality (BCM), and overall mortality (OM). A secondary aim was to detect differences by BC subtypes (ER/PR-positive/HER2-negative, HER2-positive, triple-negative). Cox models were fitted for each end-point, adjusted by potential confounders. Results: Analyses adjusting for age, tumor size, nodal status, menopausal status, surgery, grade, hormone receptor and HER2 status, chemotherapy regimen, and undertreatment showed that obese patients (BMI 30.0–34.9) had similar prognoses to that of patients with a BMI&lt;25 (reference group) in terms of recurrence (HR 1.08 [95% CI 0.9–1.3]; p=0.41), BCM (HR 1.02 [0.81–1.29]; p=0.85), and OM (HR 0.97 [0.78–1.19]; p=0.747). Patients with severe obesity (BMI≥35) had a significantly increased risk of recurrence (HR 1.26 [1.00–1.59]; p=0.05), BCM (HR 1.32 [1.00–1.74]; p=0.05), and OM (HR 1.35 [1.06–1.71]; p=0.02) compared to our reference group (Table). The prognostic effect of severe obesity did not vary by subtype. Conclusions: Severely obese patients treated with anthracyclines and taxanes present a worse prognosis regarding recurrence, BCM, and OM than patients with a BMI&lt;25. The magnitude of the harmful effect of BMI was similar across subtypes. [Table: see text]
ASSOCIATION OF ANKLE BRACHIAL INDEX AND HEMOGLOBIN A1C WITH ALL-CAUSE AND CARDIOVASCULAR MORTALITY: RESULTS FROM THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY 1999 TO 2000
Authors: Rehan Malik, Zubair Shah, James Vacek, Deepak Parashara, Buddhadeb Dawn, Kamal Gupta, Salman Waheed
Journal: Journal of the American College of Cardiology (2017)
CORONARY ARTERY CALCIUM SCORES FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK STRATIFICATION IN SMOKERS: MESA
Authors: John Leigh, John McEvoy, Veit Sandfort, Waqas Qureshi, John Carr, Elizabeth C. Oelsner, Matthew Budoff, David Herrington, Joseph Yeboah
Journal: Journal of the American College of Cardiology (2017)
The Number of RUNX1 Mutations and the Presence of One Intact RUNX1 Allele Influence Cytogenetic Abnormalities, Additional Molecular Mutations and Prognosis in RUNX1 Mutated AML
Authors: Anna Stengel, Wolfgang Kern, Manja Meggendorfer, Karolina Perglerová, Torsten Haferlach, Claudia Haferlach
Journal: Blood (2016)
COMPARING TEE WITH ANGIOGRAPHIC SIZING OF WATCHMAN DEVICE FOR LEFT ATRIAL APPENDAGE CLOSURE
Authors: Divya Ratan Verma, Haidar Yassin, Jessica Weiss, Salem Al Rabadi, Supriya Bhardwaj, Michael Morris, George Gellert, Akil Loli, H. Kenith Fang, Timothy Byrne, Ashish Pershad
Journal: Journal of the American College of Cardiology (2017)
Circulating tumor cells: Tools for monitoring and targets for therapy
Authors: K. Pachmann, O. Camara, K. Lobodasch, R. Dengler, I. Runnebaum, K. Hoeffken, U. Pachmann
Journal: Journal of Clinical Oncology (2006)

617 Background: Analysis of peripheral blood may help to early monitor the process of dissemination of metastatic cells into vital organs . The true number of circulating epithelial tumor cells (CETC) being still controversial, we, omitting all possibly selective enrichment procedures, detect a considerable number of such cells in breast cancer patients. CETC have been shown to respond to therapy in exactly the same way as the primary tumor and we have now probed CETC for monitoring effectiveness of adjuvant therapy. Methods: CETC were monitored in 97 patients before and after each cycle during adjuvant therapy using fluorchrome labeled antibody against epithelial antigen and laser scanning fluorimetry. Results: CETC could be detected in all patients after surgery. Four different forms of therapy response were observed: Patients with 1) CETC from ER+PR+ tumors responding only marginally with appreciable numbers remaining after therapy. These patients (about 40% of patients) have remained in CR; 2) rapidly decreasing CETC,sometimes to below the threshold of detection. These patients, too, remained in CR; 3) constantly or intermittently increasing resistant cells. All these patients have experienced early relapse 5–24 months after diagnosis); 4) Most interestingly, some cells initially respond very well to therapy but show a renewed increase during continuing therapy. These patients, too, have relapsed. Conclusion: Prognostic factors deduced from the primary tumor cannot predict outcome for the individual patient, whereas our approach monitoring CETC allows real-time survey of therapy response in individual patients. We confirm the observation of low responsiveness of ER+ tumors also in disseminated cells, with dormant CETC in most cases, not eliminated by current therapies but also not leading to early relapse. In contrast, most patients with CETC increasing during therapy suffer early relapse. This indicates not only that these cells are an important indicator of imminent relapse but also distant metastases may be the result of growth or regrowth of these cells. In some patients treatment influences subpopulations differently with a resistant population emerging responsible for relapse. No significant financial relationships to disclose.
IMPROVEMENT IN CHOLESTEROL EFFLUX CAPACITY IS ASSOCIATED WITH A REDUCTION IN AORTIC WALL THICKNESS BY MRI INDEPENDENT OF TRADITIONAL CV RISK FACTORS
Authors: Mohammad Tarek Kabbany, Amit Dey, Parag Shukla, Abhishek Chaturvedi, Anshuma Rana, Joshua Rivers, Jonathan Chung, Aditya Joshi, Joseph Lerman, Tsion Aberra, Justin Rodante, Heather Teague, Joanna Silverman, Qimin Ng, Mark Ahlman, Martin Playford, Nehal Mehta
Journal: Journal of the American College of Cardiology (2017)
Ultrasound Molecular Imaging With BR55 in Patients With Breast and Ovarian Lesions: First-in-Human Results
Authors: Jürgen K. Willmann, Lorenzo Bonomo, Antonia Carla Testa, Pierluigi Rinaldi, Guido Rindi, Keerthi S. Valluru, Gianluigi Petrone, Maurizio Martini, Amelie M. Lutz, Sanjiv S. Gambhir
Journal: Journal of Clinical Oncology (2017)

Purpose We performed a first-in-human clinical trial on ultrasound molecular imaging (USMI) in patients with breast and ovarian lesions using a clinical-grade contrast agent (kinase insert domain receptor [KDR] –targeted contrast microbubble [MB KDR ]) that is targeted at the KDR, one of the key regulators of neoangiogenesis in cancer. The aim of this study was to assess whether USMI using MB KDR is safe and allows assessment of KDR expression using immunohistochemistry (IHC) as the gold standard. Methods Twenty-four women (age 48 to 79 years) with focal ovarian lesions and 21 women (age 34 to 66 years) with focal breast lesions were injected intravenously with MB KDR (0.03 to 0.08 mL/kg of body weight), and USMI of the lesions was performed starting 5 minutes after injection up to 29 minutes. Blood pressure, ECG, oxygen levels, heart rate, CBC, and metabolic panel were obtained before and after MB KDR administration. Persistent focal MB KDR binding on USMI was assessed. Patients underwent surgical resection of the target lesions, and tissues were stained for CD31 and KDR by IHC. Results USMI with MB KDR was well tolerated by all patients without safety concerns. Among the 40 patients included in the analysis, KDR expression on IHC matched well with imaging signal on USMI in 93% of breast and 85% of ovarian malignant lesions. Strong KDR-targeted USMI signal was present in 77% of malignant ovarian lesions, with no targeted signal seen in 78% of benign ovarian lesions. Similarly, strong targeted signal was seen in 93% of malignant breast lesions with no targeted signal present in 67% of benign breast lesions. Conclusion USMI with MB KDR is clinically feasible and safe, and KDR-targeted USMI signal matches well with KDR expression on IHC. This study lays the foundation for a new field of clinical USMI in cancer.
Prospective analysis of qol in patients undergoing concurrent chemotherapy and radiation therapy for locally advanced head and neck cancer.
Authors: Dukagjin Blakaj, Paola Godoy-Scripes, William Kempton Skinner, Shankar Viswanathan, Hilda Haynes, Yoko Eng, Catherine Sarta, Missak Haigentz, Bradley A. Schiff, Richard V. Smith, Chandan Guha, Shalom Kalnicki, Madhur Garg
Journal: Journal of Clinical Oncology (2012)

e16058 Background: This is a prospective analysis of quality of life (QoL) in patients undergoing concurrent chemotherapy and IMRT for locally advanced head and neck cancers. Methods: In a prospective IRB approved study, patients undergoing concurrent chemotradio therapy for head and neck cancers at AECOM/MMC completed a QoL survey (EORTC QLQ-C30 and QLQ-H&amp;N 35) pretreatment, during radiation therapy, and at 1, 3 and 6 months after completion. The patients were re-simulated for adaptive planning midway through their treatment. Patients were treated to 66-70Gy (2-2.12 Gy/Fraction) to the primary and 54 to 60Gy (1.64-1.8 Gy/fraction) to the subclinical and high risk areas. Swallowing complex (SC) (base of tongue, constrictor muscles, proximal esophagus and oral cavity) were contoured as avoidance structures along with other critical structures. QoL scores were correlated with radiation dose to swallowing complex to evaluate relationships. Results: The Global Heath Status and Physical Functioning scores fell (mean 58.33 SD 35.36) during the first week of therapy before recovering at the end of second week. There is a 2nd dip in functioning scores at 4th week subsequent to which the scores rise and stabilized. The nausea/vomiting scores correlate with the timing of chemotherapy whereas the pain scores are highest at the second week mark before declining gradually. The mean swallowing specific score is worst at 5 weeks (61.11 SD 31.43) and recover gradually thereafter to level better than pre-RT score at 6-months follow-up. Conclusions: Most studies have reported QoL changes before and after treatment and have not looked at the changes during RT. One would imagine that QoL scores would gradually deteriorate throughout radiation therapy and should be the worst towards the end. In our experience, most of the QoL scores stabilize during the latter half of radiation therapy. This may be a result of multidisciplinary patient care, adaptive radiation therapy as well as tumor response to chemo-radiation therapy. Matched pair analysis is underway to compare dosimetric data and correlate this with QoL results.
Absence of functional fetal regulatory T cells in humans causes in utero organ-specific autoimmunity
Authors: Eric J. Allenspach, Laura S. Finn, Mara H. Rendi, Ahmet Eken, Akhilesh K. Singh, Mohamed Oukka, Sean D. Taylor, Matthew C. Altman, Corinne L. Fligner, Hans D. Ochs, David J. Rawlings, Troy R. Torgerson
Journal: Journal of Allergy and Clinical Immunology (2017)
INSTANTANEOUS WAVE-FREE RATIO SCOUT PULLBACK (IFR SCOUT) PRE-ANGIOPLASTY PREDICTS HEMODYNAMIC OUTCOME IN HUMANS WITH CORONARY ARTERY DISEASE: PRIMARY RESULTS OF INTERNATIONAL MULTICENTRE IFR GRADIENT REGISTRY
Authors: Christopher Cook, Yuetsu Kikuta, Andrew Sharp, Pablo Salinas, Masafumi Nakayama, Gilbert Wijntjens, Sayan Sen, Ricardo Petraco da Cunha, Rasha Al-Lamee, Sukhjinder Nijjer, Atsushi Mizuno, Martin Mates, Luc Janssens, Farrel Hellig, Kazunori Horie, John Davies, Masahiro Yamawaki, Thomas Keeble, Flavio Ribichini, Ciro Indotfi, Jan Piek, Carlo Di Mario, Javier Escaned, Hitoshi Matsuo, Justin Davies
Journal: Journal of the American College of Cardiology (2017)
IMPACT OF HOME MONITORING PROGRAM ON INTERSTAGE MORTALITY AND STAGE II OUTCOMES
Authors: Monique Gardner, Laura Mercer-Rosa, Katherine Bates, Alyson Stagg, Shobha Natarajan, Anita Szwast, Jessica (Jie) Tang, Stephanie Fuller, Christopher Mascio, Desiree Fleck, Deborah L. Torowicz, Therese Giglia, Jonathan Rome, Chitra Ravishankar
Journal: Journal of the American College of Cardiology (2017)
Haploidentical Bone Marrow Transplant with Post-Transplant Cytoxan Plus Thiotepa Improves Donor Engraftment in Patients with Sickle Cell Anemia: Results of an International Multicenter Learning Collaborative
Authors: Nathalie Dhedin, Josu de la Fuente, Francoise Bernaudin, Mathieu Kuentz, Leena Karnik, Tatsuki Koyama, Robert A. Brodsky, Michael DeBaun, Adetola A. Kassim
Journal: Blood (2016)
MTORS INHIBITORS INCREASE ENDOTHELIAL PERMEABILITY AND PREVENT MATURATION: UNCOVERING THE MECHANISM OF NEOATHEROSCLEROSIS IN DRUG ELUTING STENTS
Authors: Emanuel Harari, Frank Kolodgie, Liang Guo, Eduardo Acampado, Matthew Kutyna, Hiroyoshi Mori, Samantha Smith, Aloke Finn, Renu Virmani
Journal: Journal of the American College of Cardiology (2017)
Varicella Zoster Virus Reactivation with the Use of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients.
Authors: Seok Jin Kim, Hyo-Jin Lee, Hawk Kim, Kihyun Kim, Jae-Yong Kwak, Seung-Hyun Nam, Jung Hye Kwon, Sang Kyun Sohn, Jong-Ho Won, Jae Hoon Lee, Cheolwon Suh, Sung-Soo Yoon, Yongjun Cha, Hye Jin Kim, Inho Kim, Young-Rok Do, Won-Sik Lee, Young-Don Joo, Hyo Jung Kim
Journal: Blood (2007)
Effect of Moderate-Intensity Exercise Training on Peak Oxygen Consumption in Patients With Hypertrophic Cardiomyopathy
Authors: Sara Saberi, Matthew Wheeler, Jennifer Bragg-Gresham, Whitney Hornsby, Prachi P. Agarwal, Anil Attili, Maryann Concannon, Annika M. Dries, Yael Shmargad, Heidi Salisbury, Suwen Kumar, Jonathan J. Herrera, Jonathan Myers, Adam S. Helms, Euan A. Ashley, Sharlene M. Day
Journal: JAMA (2017)

<h3>Importance</h3> Formulating exercise recommendations for patients with hypertrophic cardiomyopathy is challenging because of concern about triggering ventricular arrhythmias and because a clinical benefit has not been previously established in this population. <h3>Objective</h3> To determine whether moderate-intensity exercise training improves exercise capacity in adults with hypertrophic cardiomyopathy. <h3>Design, Setting, and Participants</h3> A randomized clinical trial involving 136 patients with hypertrophic cardiomyopathy was conducted between April 2010 and October 2015 at 2 academic medical centers in the United States (University of Michigan Health System and Stanford University Medical Center). Date of last follow-up was November 2016. <h3>Interventions</h3> Participants were randomly assigned to 16 weeks of moderate-intensity exercise training (n = 67) or usual activity (n = 69). <h3>Main Outcomes and Measures</h3> The primary outcome measure was change in peak oxygen consumption from baseline to 16 weeks. <h3>Results</h3> Among the 136 randomized participants (mean age, 50.4 [SD, 13.3] years; 42% women), 113 (83%) completed the study. At 16 weeks, the change in mean peak oxygen consumption was +1.35 (95% CI, 0.50 to 2.21) mL/kg/min among participants in the exercise training group and +0.08 (95% CI, −0.62 to 0.79) mL/kg/min among participants in the usual-activity group (between-group difference, 1.27 [95% CI, 0.17 to 2.37];<i>P</i> = .02). There were no occurrences of sustained ventricular arrhythmia, sudden cardiac arrest, appropriate defibrillator shock, or death in either group. <h3>Conclusions and Relevance</h3> In this preliminary study involving patients with hypertrophic cardiomyopathy, moderate-intensity exercise compared with usual activity resulted in a statistically significant but small increase in exercise capacity at 16 weeks. Further research is needed to understand the clinical importance of this finding in patients with hypertrophic cardiomyopathy, as well as the long-term safety of exercise at moderate and higher levels of intensity. <h3>Trial Registration</h3> clinicaltrials.gov Identifier:NCT01127061
PERCUTANEOUS CLOSURE OF PATENT FORAMEN OVALE IS ASSOCIATED WITH LOWER INCIDENCE CRYPTOGENIC STROKES AMONG PATIENTS WITH INHERITED THROMBOPHIALIAS TREATED WITH ANTICOAGULANT OR ANTIAGGREGANT THERAPY
Authors: Yonatan Buber, David Orion, Sharon Borik, Ori Varuri, Victor Guetta
Journal: Journal of the American College of Cardiology (2017)
EARLY, LATE AND VERY LATE INCIDENCE OF BIORESORBABLE SCAFFOLD THROMBOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS AND OBSERVATIONAL REGISTRIES
Authors: Carlos A. Collet, Patrick Serruys, Robbert de Winter, Taku Asano, Yoshinobu Onuma, Yosuke Miyazaki, Yohei Sotomi, Erhan Tenekecioglu, Rafael Cavalcante, Davide Capodanno
Journal: Journal of the American College of Cardiology (2017)
The Integrated Immunological Signature of Refractory Cytopenia of Childhood (RCC)
Authors: Demi de Winter, Marry M van den Heuvel-Eibrink, Vincent H.J. van der Velden, Anton W. Langerak, Jacques J.M. Dongen, Michael Dworzak, Barbara De Moerloose, Jan Starý, Charlotte M Niemeyer, Franco Locatelli, Henrik Hasle, Markus Schmugge, C. Michel Zwaan, Rob Pieters
Journal: Blood (2015)